Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressive disease characterized by deposition of amyloid fibrils in various organs and tissues of the body. There are a wide variety of clinical presentations for this multisystemic disorder, so it is often misdiagnosed or subject to delayed diagnosis. Although the exact prevalence is difficult to determine, existing estimates suggest a worldwide prevalence of 50,000 individuals, with varying phenotypic presentations of disease. Due to the heterogeneous nature of its presentation, incorrect or delayed diagnosis can severely impact quality of life for these patients. hATTR amyloidosis can lead to significant disability and mortality. After an accurate diagnosis of hATTR amyloidosis is established, new patients should undergo appropriate therapy as soon as possible. Current treatment options for hATTR amyloidosis are limited, but orthotopic liver transplant serves as an established option for patients with early-stage disease. Consequently, there is a need for new, effective, and safe therapies.

Original languageEnglish (US)
Pages (from-to)S107-S112
JournalThe American journal of managed care
Volume23
Issue number7
StatePublished - Jun 1 2017

Fingerprint

Familial Amyloidosis
Cost of Illness
Delayed Diagnosis
Diagnostic Errors
Amyloid
Therapeutics
Quality of Life
Transplants
Mortality
Amyloidosis, Hereditary, Transthyretin-Related
Liver

ASJC Scopus subject areas

  • Health Policy

Cite this

Hereditary ATTR amyloidosis : burden of illness and diagnostic challenges. / Gertz, Morie.

In: The American journal of managed care, Vol. 23, No. 7, 01.06.2017, p. S107-S112.

Research output: Contribution to journalReview article

@article{81f8769659904425a1e48e26558973c3,
title = "Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges",
abstract = "Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressive disease characterized by deposition of amyloid fibrils in various organs and tissues of the body. There are a wide variety of clinical presentations for this multisystemic disorder, so it is often misdiagnosed or subject to delayed diagnosis. Although the exact prevalence is difficult to determine, existing estimates suggest a worldwide prevalence of 50,000 individuals, with varying phenotypic presentations of disease. Due to the heterogeneous nature of its presentation, incorrect or delayed diagnosis can severely impact quality of life for these patients. hATTR amyloidosis can lead to significant disability and mortality. After an accurate diagnosis of hATTR amyloidosis is established, new patients should undergo appropriate therapy as soon as possible. Current treatment options for hATTR amyloidosis are limited, but orthotopic liver transplant serves as an established option for patients with early-stage disease. Consequently, there is a need for new, effective, and safe therapies.",
author = "Morie Gertz",
year = "2017",
month = "6",
day = "1",
language = "English (US)",
volume = "23",
pages = "S107--S112",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "7",

}

TY - JOUR

T1 - Hereditary ATTR amyloidosis

T2 - burden of illness and diagnostic challenges

AU - Gertz, Morie

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressive disease characterized by deposition of amyloid fibrils in various organs and tissues of the body. There are a wide variety of clinical presentations for this multisystemic disorder, so it is often misdiagnosed or subject to delayed diagnosis. Although the exact prevalence is difficult to determine, existing estimates suggest a worldwide prevalence of 50,000 individuals, with varying phenotypic presentations of disease. Due to the heterogeneous nature of its presentation, incorrect or delayed diagnosis can severely impact quality of life for these patients. hATTR amyloidosis can lead to significant disability and mortality. After an accurate diagnosis of hATTR amyloidosis is established, new patients should undergo appropriate therapy as soon as possible. Current treatment options for hATTR amyloidosis are limited, but orthotopic liver transplant serves as an established option for patients with early-stage disease. Consequently, there is a need for new, effective, and safe therapies.

AB - Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressive disease characterized by deposition of amyloid fibrils in various organs and tissues of the body. There are a wide variety of clinical presentations for this multisystemic disorder, so it is often misdiagnosed or subject to delayed diagnosis. Although the exact prevalence is difficult to determine, existing estimates suggest a worldwide prevalence of 50,000 individuals, with varying phenotypic presentations of disease. Due to the heterogeneous nature of its presentation, incorrect or delayed diagnosis can severely impact quality of life for these patients. hATTR amyloidosis can lead to significant disability and mortality. After an accurate diagnosis of hATTR amyloidosis is established, new patients should undergo appropriate therapy as soon as possible. Current treatment options for hATTR amyloidosis are limited, but orthotopic liver transplant serves as an established option for patients with early-stage disease. Consequently, there is a need for new, effective, and safe therapies.

UR - http://www.scopus.com/inward/record.url?scp=85047903553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047903553&partnerID=8YFLogxK

M3 - Review article

C2 - 28978215

AN - SCOPUS:85047903553

VL - 23

SP - S107-S112

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 7

ER -